دیگر

ARMO BioSciences Proposes Terms For $100 U.S. IPO

Summary

ARMO BioSciences intends to raise $100 million in a U.S. IPO.

The firm is developing a promising pipeline of immuno-based treatments for some of the deadliest forms of cancer.

Given the potential of its lead candidate, its late stage of development and existing investor support of the IPO, ARMO may have a winning drug treatment.

Quick Take

ARMO BioSciences (ARMO) has proposed terms to raise $100 million in a U.S. IPO.

The company is a late stage immuno-oncology firm developing candidates to stimulate the patient’s immune system to reduce or eliminate cancerous tumors.

ARMO has a very promising lead candidate (AM0010) for the deadliest form of cancer, pancreatic ductal adenocarcinoma, which has begun Phase 3 trials.

Company Recap

Redwood City, CA-based ARMO BioSciences was founded in 2013 as an immuno-oncology company to develop product candidates that exploit and enhance the body’s immune system to treat various diseases.

Management is headed by Founder, President, and CEO Peter Van Vlasselaer. Vlasselaer previously served as the interim president, CEO, and on the board of directors of iPierian from April 2011 to August 2011.

The company’s lead product candidate is AM0010, a long-acting form of human interleukin-10 (a naturally occurring immune cell growth factor in humans). ARMO’s initial focus is treating patients with pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC).

The firm is in Phase 3 clinical trials for PDAC patients with metastatic stage IV cancer and is launching Phase 2B trials for patients with NSCLC.

☑Read more

عضویت در کانال زیست فن☑

ARMO BioSciences Proposes Terms For $100 U.S. IPO

Rate this post
برچسب‌ها
نمایش بیشتر

نوشته‌های مشابه

دیدگاهتان را بنویسید

نشانی ایمیل شما منتشر نخواهد شد. بخش‌های موردنیاز علامت‌گذاری شده‌اند *

دکمه بازگشت به بالا
EnglishIran
بستن
بستن